Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“Dr. Anne-Marie Dingemans starts a discussion on marginally resectable and unresectable NSCLC at BTGGlobalLung2025.
Concurrent chemoradiation and consolidation durvalumab remains the standard for unresectable stage III NSCLC. For resectable N2+, perioperative chemoIO outcomes encouraging.”
More posts featuring NSCLC.
